Anal Cancer clinical trials

Explore recruiting anal cancer clinical trials.

Recruiting anal cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Anal Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PHASE 1B/II TRIAL OF CHECKPOINT INHIBITOR (PEMBROLIZUMAB AND ANTI PD-1 ANTIBODY) PLUS STANDARD IMRT IN HPV INDUCED STAGE III SQUAMOUS CELL CARCINOMA OF ANUS

Norway

Phase I and Phase II (Integrated)- Bioequivalence Study EU CTIS Study details

RADIANCE Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma; A multicenter, randomized, phase II trial of the German Anal Cancer Study Group

Austria, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase Ib/II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies

Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1b, Open-Label, Dose-Escalation Trial of the Safety of and Antigen-Specific Immune Responses Elicited by VB.10 NEO in Combination With Atezolizumab in Subjects with Locally Advanced and Metastatic Tumors

Germany, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers exploring treatment comBinations with peLarEorep and aTezolizumab (GOBLET)

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers

Italy, Spain, France, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Anal Cancer trials by city

Anal Cancer in Toronto Anal Cancer in Vancouver Anal Cancer in Montreal Anal Cancer in Calgary Anal Cancer in Edmonton Anal Cancer in Ottawa Anal Cancer in Winnipeg Anal Cancer in Quebec City Anal Cancer in Hamilton Anal Cancer in Kitchener Anal Cancer in London Anal Cancer in Halifax Anal Cancer in New York Anal Cancer in Los Angeles Anal Cancer in Chicago Anal Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease